- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Innovotech Inc: Innovotech loses $655,700 in Q2 | 1 | Stockwatch | ||
| INNOVOTECH Aktie jetzt für 0€ handeln | |||||
| 18.08. | Innovotech Inc. Reports Q2 2026 Financial Results | 2 | TheNewswire | ||
| 14.08. | Innovotech Inc. Launches of InnovoTEST Hazardous Drug Wipe Testing Kits to Support Pharmacy Compliance and Healthcare Worker Safety | 2 | TheNewswire | ||
| 16.06. | Innovotech Inc. Announces CFO Transition and Reports 2026 Annual General Meeting Result | 2 | TheNewswire | ||
| 14.05. | Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements | 2 | TheNewswire | ||
| 12.05. | Innovotech Inc. Reports Q1 2026 Financial Results and Operational Update | 1 | TheNewswire | ||
| 12.05. | Innovotech reports Q1 results | 1 | Seeking Alpha | ||
| 30.04. | Fendx Technologies Inc (2): Fendx hires Innovotech for Foley regulatory pathway | 8 | Stockwatch | ||
| 30.04. | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | 1.230 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| 15.04. | Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors | 1 | TheNewswire | ||
| 01.04. | Innovotech Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results | 1 | TheNewswire | ||
| 26.01. | DealFlow Events: Innovotech Inc. Presenting at the 3rd Annual DealFlow Discovery Conference | 374 | ACCESS Newswire | EDMONTON, AB / ACCESS Newswire / January 26, 2026 / Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary antimicrobial testing and advanced laboratory services... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARTELO BIOSCIENCES | 7,300 | -0,14 % | Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings | As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,460 | +0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 282,42 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,040 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| RECURSION PHARMACEUTICALS | 3,700 | 0,00 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| ABSCI | 9,745 | 0,00 % | Anlegervertrauen zerstört: 80 Millionen Betroffene: Novo greift nach dem Milliardenmarkt Haarausfall | © Foto: Frank Hoermann / SVEN SIMON - SVEN SIMONNovo Nordisk sucht Wachstum jenseits von Wegovy - und nimmt jetzt einen überraschenden Milliardenmarkt mit 80 Millionen Betroffenen allein in den USA... ► Artikel lesen | |
| QIAGEN | 38,510 | +0,26 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| IMMUNOVANT | 34,560 | +0,06 % | Immunovant ends cutaneous lupus program after phase 2 flop | ||
| DYNE THERAPEUTICS | 16,230 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 16,445 | -0,03 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| KYMERA THERAPEUTICS | 115,41 | -0,05 % | Piper Sandler reiterates Kymera Therapeutics stock rating at $140 | ||
| COGENT BIOSCIENCES | 31,405 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,040 | 0,00 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,380 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,035 | +0,03 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen |
INNOVOTECH INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOVOTECH INC finden Sie auf Wallstreet Online.